(Q36194538)

12 August 2017

1 reference

title

A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation (English)

1 reference

12 August 2017

1 reference

1 reference

Andreas Reiff

1

1 reference

12 August 2017

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

10

1 reference

12 August 2017

2

1 reference

12 August 2017

79-93

1 reference

Recognition of CD52 allelic gene products by CAMPATH-1H antibodies

12 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

The effect of treatment with Campath-1H in patients with autoimmune cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti‐CD52 monoclonal antibody alemtuzumab (Campath‐1H)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Campath-1H therapy in refractory ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Management of severe scleroderma with long-term extracorporeal photopheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Recognition and management of scleroderma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Classification and treatment of the juvenile idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Treatment of refractory autoimmune diseases with ablative immunotherapy using monoclonal antibodies and/or high dose chemotherapy with hematopoietic stem cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

Treatment of refractory autoimmune diseases with ablative immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

"Infectious" transplantation tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330400026139

10.1080/10245330400026139

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16019453